HELX250117C30000
- 0.00
- 0.000.00%
Franklin Genomic Advancements Etf Newsroom
Elon Musk Says He Prefers Lilly's Mounjaro Over Novo's Ozempic
Express News | Lilly's weight loss medication is now available for purchase on e-commerce platforms in China
Eli Lilly's Weight Loss Med Tirzepatide Gets Endorsement From U.K.'s NICE
Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years
Eli Lilly Stock Is Rising Monday: What's Going On?
14 Analysts Have This To Say About Danaher
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
ResMed, Inspire Medical Fall After Lilly's Zepbound Gains Sleep Apnea Indication
Danaher Analyst Ratings
Thermo Fisher Scientific Analyst Ratings
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $500
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.